Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away

2026-03-06 08:37:16 ET

Thesis

Altimmune, Inc. ( ALT ) has just reported a 4Q25 GAAP EPS of -$0.27, a figure which missed analyst expectations by about $0.03. Now, even with the earnings miss, the company did still manage to post some revenue, about of $0.03 million, which actually exceeded the consensus by about the same margin. It was also a bit of an improvement over the $5,000 in revenue we saw last year. The company also managed to set up a pretty decent cash position at $274 million going into 2026. We also got an update on some significant operational progress on the call, especially surrounding pemvidutide. As a reminder, the candidate is a dual glucagon/GLP-1 receptor agonist being developed for some pretty serious liver diseases, such as MASH....

Read the full article on Seeking Alpha

For further details see: